Bausch+Lomb Results Presentation Deck

1Q23 Company Highlights 5% 8% Bausch + Lomb 1023 vs. 1022 1Q23 Reported Revenue Growth 1Q23 Constant Currency Revenue Growth ¹ Ophthalmic Pharmaceuticals 17% $931M Surgical Reported 20% Revenue BAUSCH + LOMB Vision Care 63% $141 M Adj. EBITDA¹ $14M headwind from FX 61% Continued Strong Revenue Growth Across All Three Segments Surgical Vision Care² $587M Consumer 39% Contact Lens 1Q 23 CONSTANT +8% Solid growth in key franchises including Lumify®, Daily SiHy, Biotrue® ONEday and ULTRA® 52% $183M Implantables 24% 24% Equipment Consumables/Other Ophthalmic Pharmaceuticals ² +9% Increased demand, improving supply and expanded premium IOL portfolio 59% CURRENCY REVENUE $161 M U.S. 41% International CHANGE 1. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios. 2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure. 1 +7% Strong U.S. generic execution and International portfolio growth 7

View entire presentation